Pexidartinib and Quin-G

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer information for this interaction is not currently available.MONITOR: Coadministration with pexidartinib may increase the plasma concentrations and risk of adverse effects of drugs that are substrates of P-glycoprotein (P-gp). The proposed mechanism is decreased clearance due to pexidartinib-mediated inhibition of P-gp. Concomitant administration of a single oral dose of pexidartinib (1800 mg) increased the peak plasma concentration (Cmax) and systemic exposure (AUC) of digoxin, a P-gp substrate, by 30% and 9%, respectively, compared with digoxin alone. MANAGEMENT: Caution is advised if pexidartinib is used concomitantly with drugs that are substrates of P-gp, particularly those with a narrow therapeutic range. The potential for diminished therapeutic effects should be considered when pexidartinib is prescribed in combination with drugs that are P-gp substrates. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever pexidartinib is added to or withdrawn from therapy with these drugs. An alternative agent with no or minimal P-gp-inhibiting activity may also be considered. References "Product Information. Turalio (pexidartinib)." Daiichi Sankyo, Inc., Parsippany, NJ.

MONITOR: Coadministration with pexidartinib may increase the plasma concentrations and risk of adverse effects of drugs that are substrates of P-glycoprotein (P-gp). The proposed mechanism is decreased clearance due to pexidartinib-mediated inhibition of P-gp. Concomitant administration of a single oral dose of pexidartinib (1800 mg) increased the peak plasma concentration (Cmax) and systemic exposure (AUC) of digoxin, a P-gp substrate, by 30% and 9%, respectively, compared with digoxin alone.

MANAGEMENT: Caution is advised if pexidartinib is used concomitantly with drugs that are substrates of P-gp, particularly those with a narrow therapeutic range. The potential for diminished therapeutic effects should be considered when pexidartinib is prescribed in combination with drugs that are P-gp substrates. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever pexidartinib is added to or withdrawn from therapy with these drugs. An alternative agent with no or minimal P-gp-inhibiting activity may also be considered.

Pexidartinib

Generic Name: pexidartinib

Brand name: Turalio

Synonyms: n.a.

What is Pexidartinib?

Quin-G

Generic Name: quinidine

Brand name: Quin-G, Cardioquin, Quinora, Quinidex Extentabs, Quinaglute Dura-Tabs, Quin-Release

Synonyms: n.a.

What is Quin-G?